Overview Dividends

(CURI) Curiositystream - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23130Q1076

Documentaries, Streaming, Subscription, Licensing

CURI EPS (Earnings per Share)

EPS Growth (3Y CAGR): 33.88%
EPS Trend (3Y Correlation): 71.8%

CURI Revenue

Revenue Growth (3Y CAGR): -7.52%
Revenue Trend (3Y Correlation): -16.4%

Description: CURI Curiositystream October 26, 2025

CuriosityStream Inc. (NASDAQ:CURI) is a U.S.-based media and entertainment firm that produces factual, documentary-style video and audio content across science, history, society, nature, lifestyle and technology. The library is delivered directly to consumers via its subscription-video-on-demand (SVoD) platform on internet-connected devices, and indirectly through distribution partners that bundle CuriosityStream titles into larger streaming or linear packages, as well as through bulk-sale licensing, educational talks and courses.

Key operating metrics as of the latest filing show roughly 5 million global subscribers with an average revenue per user (ARPU) of $4.90 per month and a churn rate near 8 % annually-both in line with niche streaming peers. The company’s growth is tied to macro trends such as continued cord-cutting, rising demand for ad-free, niche-content subscriptions, and the expanding global broadband penetration that fuels device-agnostic streaming. Margin improvement has been driven by a low-cost, in-house production model and scalable licensing agreements, allowing EBITDA margins to edge above 15 % in 2023.

For a deeper quantitative assessment, you might explore ValueRay’s analyst tools to compare CuriosityStream’s valuation multiples against sector peers and test scenario sensitivities.

CURI Stock Overview

Market Cap in USD	251m
Sub-Industry	Movies & Entertainment
IPO / Inception	2020-01-08

CURI Stock Ratings

Growth Rating	60.9%
Fundamental	44.8%
Dividend Rating	51.2%
Return 12m vs S&P 500	52.7%
Analyst Rating	4.0 of 5

CURI Dividends

Dividend Yield 12m	7.33%
Yield on Cost 5y	3.66%
Annual Growth 5y	0.00%
Payout Consistency	100.0%
Payout Ratio	0.0%

CURI Growth Ratios

Growth Correlation 3m	35.5%
Growth Correlation 12m	80%
Growth Correlation 5y	-42.3%
CAGR 5y	56.75%
CAGR/Max DD 3y (Calmar Ratio)	0.75
CAGR/Mean DD 3y (Pain Ratio)	1.60
Sharpe Ratio 12m	-0.05
Alpha	49.21
Beta	1.865
Volatility	74.45%
Current Volume	279.8k
Average Volume 20d	389.6k
Stop Loss	3.8 (-7.1%)
Signal	-0.52

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (-4.77m TTM) > 0 and > 6% of Revenue (6% = 3.65m TTM)

FCFTA 0.13 (>2.0%) and ΔFCFTA 15.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 26.36% (prev 44.98%; Δ -18.62pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 10.0m > Net Income -4.77m (YES >=105%, WARN >=100%)

Net Debt (17.9m) to EBITDA (3.03m) ratio: 5.92 <= 3.0 (WARN <= 3.5)

Current Ratio 1.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (57.4m) change vs 12m ago 6.98% (target <= -2.0% for YES)

Gross Margin 53.07% (prev 46.40%; Δ 6.66pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 71.78% (prev 60.30%; Δ 11.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -7.95 (EBITDA TTM 3.03m / Interest Expense TTM 1.70m) >= 6 (WARN >= 3)

Altman Z'' -24.55

(A) 0.20 = (Total Current Assets 40.5m - Total Current Liabilities 24.4m) / Total Assets 78.7m

(B) -4.05 = Retained Earnings (Balance) -318.6m / Total Assets 78.7m

warn (B) unusual magnitude: -4.05 — check mapping/units

(D) -11.06 = Book Value of Equity -318.6m / Total Liabilities 28.8m

Total Rating: -24.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.77

1. Piotroski 5.50pt = 0.50

2. FCF Yield 3.69% = 1.84

3. FCF Margin 16.32% = 4.08

4. Debt/Equity 0.50 = 2.38

5. Debt/Ebitda 5.92 = -2.50

6. ROIC - WACC (= -39.35)% = -12.50

7. RoE -8.37% = -1.40

8. Rev. Trend -16.41% = -1.23

9. EPS Trend 71.85% = 3.59

What is the price of CURI shares?

As of November 06, 2025, the stock is trading at USD 4.09 with a total of 279,845 shares traded.
Over the past week, the price has changed by -12.98%, over one month by -21.19%, over three months by -11.62% and over the past year by +81.55%.

Is Curiositystream a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Curiositystream (NASDAQ:CURI) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 44.77 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CURI is around 3.62 USD . This means that CURI is currently overvalued and has a potential downside of -11.49%.

Is CURI a buy, sell or hold?

Curiositystream has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CURI.

Strong Buy: 0
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CURI price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	6.3	54.8%
Analysts Target Price	6.3	54.8%
ValueRay Target Price	4.1	1.2%

CURI Fundamental Data Overview November 03, 2025

Market Cap USD = 251.4m (251.4m USD * 1.0 USD.USD)
P/E Forward = 526.3158
P/S = 4.1324
P/B = 5.9742
Beta = 1.865
Revenue TTM = 60.8m USD
EBIT TTM = -13.5m USD
EBITDA TTM = 3.03m USD
Long Term Debt = 4.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 21.2m USD (from shortTermDebt, last quarter)
Debt = 24.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.9m USD (from netDebt column, last quarter)
Enterprise Value = 269.3m USD (251.4m + Debt 24.9m - CCE 6.94m)
Interest Coverage Ratio = -7.95 (Ebit TTM -13.5m / Interest Expense TTM 1.70m)
FCF Yield = 3.69% (FCF TTM 9.93m / Enterprise Value 269.3m)
FCF Margin = 16.32% (FCF TTM 9.93m / Revenue TTM 60.8m)
Net Margin = -7.84% (Net Income TTM -4.77m / Revenue TTM 60.8m)
Gross Margin = 53.07% ((Revenue TTM 60.8m - Cost of Revenue TTM 28.6m) / Revenue TTM)
Gross Margin QoQ = 53.38% (prev 53.08%)
Tobins Q-Ratio = 3.42 (Enterprise Value 269.3m / Total Assets 78.7m)
Interest Expense / Debt = -1.77% (Interest Expense -439.0k / Debt 24.9m)
Taxrate = -17.19% (negative due to tax credits) (-115.0k / 669.0k)
NOPAT = -15.9m (EBIT -13.5m * (1 - -17.19%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.66 (Total Current Assets 40.5m / Total Current Liabilities 24.4m)
Debt / Equity = 0.50 (Debt 24.9m / totalStockholderEquity, last quarter 49.8m)
Debt / EBITDA = 5.92 (Net Debt 17.9m / EBITDA 3.03m)
Debt / FCF = 1.81 (Net Debt 17.9m / FCF TTM 9.93m)
Total Stockholder Equity = 57.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.07% (Net Income -4.77m / Total Assets 78.7m)
RoE = -8.37% (Net Income TTM -4.77m / Total Stockholder Equity 57.0m)
RoCE = -22.14% (EBIT -13.5m / Capital Employed (Equity 57.0m + L.T.Debt 4.09m))
RoIC = -27.81% (negative operating profit) (NOPAT -15.9m / Invested Capital 57.0m)
WACC = 11.54% (E(251.4m)/V(276.3m) * Re(12.89%) + D(24.9m)/V(276.3m) * Rd(-1.77%) * (1-Tc(-0.17)))
Discount Rate = 12.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.96%
[DCF Debug] Terminal Value 52.07% ; FCFE base≈9.93m ; Y1≈6.52m ; Y5≈2.98m
Fair Price DCF = 0.56 (DCF Value 32.5m / Shares Outstanding 57.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 71.85 | EPS CAGR: 33.88% | SUE: 0.12 | # QB: 0
Revenue Correlation: -16.41 | Revenue CAGR: -7.52% | SUE: 2.84 | # QB: 1

Additional Sources for CURI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle